.Focus on: Tuberculosis

IFPMA endorses the World Health Organization’s End TB Strategy, envisioning a world free of TB with zero deaths, disease and suffering, as also recognised by the new Sustainable Development Goals. The researched-based pharmaceutical industry is involved in a wide-ranging number of initiatives to support the global health community in achieving this vision.

Our approach to the TB challenge is two-pronged focusing on increasing research & development for improved treatments and new vaccines for TB and MDR-TB, as well as partnering with others to expand access to treatment, diagnostics and care for patients. 

IFPMA member companies recognise collaboration in R&D can be instrumental in addressing the most pressing of global health challenges, allowing stakeholders to draw on their respective resources and experiences. IFPMA member companies recognise collaboration in R&D can be instrumental in addressing the most pressing of global health challenges, allowing stakeholders to draw on their respective resources and experiences. Copyright IFPMA

Tuberculosis today

Since the launch of the Millennium Development Goals in 2000, the Sustainable Development Goals in 2016 and the setting up of the Global Fund for TB, HIV/AIDs and malaria, we have seen some improvements in the landscape of TB. Since the year 2000, incidence has fallen by an average of 1.5% per year. However, this needs to accelerate to a 4–5% annual decline to reach the 2020 milestones of the "End TB Strategy" and 

Despite this decline in incidences, tuberculosis today remains one of the world’s deadliest communicable diseases. In 2015, an estimated 10.4 million people developed TB and 1.8 million died from the disease, 400,000 of whom were HIV-positive. Worldwide, an estimated 480,000 people developed multidrug-resistant TB (MDR-TB) in 2015. 

Over 95% of TB deaths occur in low- and middle-income countries. Of the estimated 10.4 million people who developed TB in 2015, more than half of new TB cases were in Asia, with 61% of new cases, followed by Africa, with 26% of new cases. 60% of tuberculosis cases worldwide ocurred in just six countries; China, India, Indonesia, Nigeria, Pakistan and South Africa. 

Doing our part

Tuberculosis is curable, but its long treatment regimen is demanding and unfortunately is difficult for patients to successfully complete, so a number of member companies are working to develop improved treatments for TB and MDR-TB, as well as to discover new vaccines to stem the spread of this disease.

Between 2012 and 2014, pharmaceutical companies have succeeded in developing 3 new treatments for MDR-TB and latent TB infection which have been approved. There are currently over 60 R&D projects for TB medicines and vaccines in the pipeline, including 11 promising products in the late stages of development and 7 in phase III clinical trials. This means that these treatments or vaccines are reaching the final stages of the 10 to 15 year R&D process; a process where many other possible treatments or vaccines have fallen by the wayside.

IFPMA member companies recognise collaboration in R&D can be instrumental in addressing the most pressing of global health challenges, allowing stakeholders to draw on their respective resources and experiences. Companies are therefore partnering with over 30 partners (universities, research institutes, product development partnerships (PDPs), etc.) to develop innovative medicines and vaccines to TB and MDR-TB. As highlighted in the latest G-Finder report, multinational pharmaceutical companies have invested USD 92m to tuberculosis R&D in 2015.

The discovery of new medicines and vaccines is essential, but equally important are measures to get these treatments to patients, wherever they may be.

IFPMA member companies are involved in 32 partnerships to increase access to TB treatment, diagnosis and care. These programs include technology transfers with generics companies in countries with a high-burden of MDR-TB to increase local capacity in the manufacturing of MDR-TB medicines and reaching isolated groups with TB diagnostics through door-to-door screenings and training of health workers. Companies work with mHealth providers to prevent medicine stock-outs in rural health centers and ensure the quality of tuberculosis medicines in pharmacies across the world with mobile labs. Furthermore, many member companies are involved in projects to support the WHO and global advocacy groups to accelerate social and political action to stop the spread of TB.

You can learn more about these programs and many others by following the link “Tuberculosis” under Partnership Information to the right.

Join us in conversations around tuberculosis using the hashtags #healthpartnerships, #tuberculosis , #EndTB and #UniteToEndTB on social media.  

More information can be found here:

Partnership information

Therapeutic Focus Infectious Diseases

Disease(s) Tuberculosis

Region(s) East Asia & Pacific, Europe & Central Asia, Latin America & Caribbean, Middle East & North Africa, North America, South Asia, Sub-Saharan Africa

Number of Countries 198

Country(ies) Afghanistan, Albania, Algeria, Andorra, Angola, Antigua and Barbuda, Argentina, Armenia, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, Brunei, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Cook Islands, Costa Rica, Côte d'Ivoire, Croatia, Cuba, Cyprus, Czech Republic, Democratic Republic of the Congo, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Ethiopia, Fiji, Finland, France, French Guiana, Gabon, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hong-Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kuwait, Kyrgyzstan, Lao PDR, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Macedonia, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, Norway, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russia, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Spain, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Tuvalu, Uganda, Ukraine, United Arab Emirates, United Kingdom, United States of America, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2000

Anticipated completion date Ongoing